Indications
Ferric maltol is prescribed for the treatment of iron deficiency in adult patients. It serves as a crucial therapy for individuals who are unable to meet their iron requirements through diet alone or those who have experienced iron loss due to various medical conditions.
Pharmacodynamics
Ferric maltol functions by supplying·h iron deficiency. It possesses a broad therapeutic index, with a standard dosage of 30 mg administered twice daily. It is important to note that concentrations reaching·hould be informed about potential risks such as exacerbation of inflammatory bowel disease, iron overload, and accidental ing·hildren, which can be hazardous.
Absorption
Upon administration, ferric maltol dissociates in the gastrointestinal tract, leading·hin 1.5 to 3.0 hours. In individuals with iron deficiency, a sing·he bioavailability of a 60 mg dose is approximately 14%. Within 60 minutes of the administration of radiolabeled ferric maltol, 11±2% of the dose can be found in the bone marrow, 18±1% in the liver, and 2.6±1% is excreted in the urine. The area under the curve (AUC) for maltol is between 0.022 and 0.205 h*µg/mL, while maltol glucuronide exhibits an AUC rang·h*µg/mL.
Metabolism
In vitro studies indicate that the metabolism of ferric maltol primarily involves the glucuronidation of maltol by the enzyme UGT1A6, along·h sulfation processes. This metabolic pathway facilitates the conversion of the active components of ferric maltol, ensuring·herapeutic efficacy while minimizing potential adverse effects.
Mechanism of Action
Ferric maltol functions by dissociating to release the iron atom, which is subsequently absorbed through possible pathways, including beta 3 integrin or divalent metal transporter 1/6, primarily within the ileum and duodenum. After absorption, the liberated iron enters circulation, where it binds to transferrin and is stored as ferritin.
